Biotech Values

[DewDiligence]

MRX is a well-run company with some desirable assets in its portfolio. I’ve followed MRX closely because it’s one of AGN’s main competitors, and I’ve always thought MRX had an ample amount of buyout vig. However, MRX is one of the least transparent drug/biotech companies I know, so it’s been a hard company to place a value on without the inside look a prospective acquirer can get via a non-disclosure agreement.

MRX’s decision to sell now may be influenced, at least in part, by CEO Jonah Shacknai’s personal tragedy last year.